

## Synthesis, Characterization, Stability and Cytotoxic Evaluation of Novel Titanium(IV) Complexes of 8-Hydroxyquinoline and 2-Hydroxy-N-phenylbenzylamine Derivatives

BLASSAN SAMUEL<sup>1,\*</sup> and MADHVESH PATHAK<sup>2</sup>

<sup>1</sup>Faculty of Education, St. Theresa International College, Bangkok-26120, Thailand

<sup>2</sup>Department of Chemistry, School of Advanced Sciences, Vellore Institute of Technology, Vellore-632014, India

\*Corresponding author: Fax: +66 3 7349936; Tel: +66 9 28707365; E-mail: [blassansamuel@gmail.com](mailto:blassansamuel@gmail.com)

Received: 19 October 2019;

Accepted: 3 December 2019;

Published online: 31 January 2019;

AJC-19778

A new class of moisture stable heteroleptic titanium(IV) complexes, synthesized from 8-hydroxyquinoline of the type  $[(Q)_2Ti(2-O-5-X-C_6H_3CH_2NC_6H_4R)]$  (**3a-j**), was prepared by reacting the antecedent molecule  $[(Q)_2Ti(OiPr)_2]$  (**2**) with various 2-hydroxy-N-phenylbenzylamine analogues in 1:1 molar ratios in dry toluene (where, HQ = 8-hydroxyquinoline; iPr = isopropyl; R = H, 4-CH<sub>3</sub>, 4-OCH<sub>3</sub>, 2-Cl, 4-Cl, 2-Br, 4-Br; X = H, Br). Moisture sensitive study disclosed that these new metal complexes were unreacted for 72 h. Mass spectral data were employed for proving the mono-nuclearity of the new derivatives. Thermal decomposition pattern of the new derivatives was explained by thermogravimetric analyses. Elemental analyses data are in concordance with their expected values. The hexa-coordinated way of titanium-ligand linkage is further proved through NMR, FTIR, and UV-visible spectral studies. The cytotoxic efficiency of new complexes was tested against MDA-MB-231 human breast carcinoma cell line. Complex **3a** exhibited the highest cytotoxic potential of 0.039  $\mu$ M in comparison to all its analogues of this series by employing cisplatin as the standard.

**Keywords:** Cytotoxicity evaluation, 8-Hydroxyquinoline, Moisture Stability, Titanium complexes.

### INTRODUCTION

Non-communicable diseases have become the leading causes of the ever-increasing mortality rate across the globe. Surprisingly, the vast majority of this decreasing life expectancy is due to cancer [1,2]. Though different kinds of drugs are using in the treatment of cancer, complete recovery from it is still a vexing issue. Metal-based drugs hold a strong history in the field of cancer research [3,4]. The success story of cisplatin, the first drug from the inorganic background, opened a new window for the scholars to initiate their research in the synthesis and biological evaluation of various metal complexes [5]. Among various metal complexes, titanium complexes become attractive to the researchers due to their low toxicity and fewer side effects [6].

A few titanium complexes such as budotitane and titanium dichloride have displayed substantial anticancer abilities against various cell lines [7]. However, their rapid hydrolysis in the moisture environment rendered failure in the clinical trial [8,9]. The Achilles heel in the titanium chemistry is the low stability

of titanium complexes in the moisture enriched conditions [10]. The vulnerability of titanium complexes towards moisture is due to the oxophilicity of the titanium atom [11]. Moisture stable complexes are highly desirable for proper biological evaluations [12].

Based on our studies, we have found that Ti(IV) complexes with short Ti-N coordination bonds have exceptional stability in the hydrous environment [11,13,14]. In view of this, 8-hydroxyquinoline (8-HQ) is selected as a potential ligand for the synthesis process. In the present series, we have synthesized different metallacyclic heteroleptic titanium(IV) derivatives by employing 8-hydroxyquinoline and various derivatives of 2-hydroxy-N-phenylbenzylamines. Furthermore, we have systematically monitored the ability of all these complexes to withstand in hydrous conditions and found that all of them are stable for 4 days. Additionally, anticancer potential of all these complexes has evaluated against MDA-MB-231 human breast carcinoma cell line by using cisplatin as the standard drug.

## EXPERIMENTAL

All the reagents were purified either by distillation or by re-crystallization and prior to the experiment were dried thoroughly. Toluene (S.D. Fine Chemicals, b.p., 110.6 °C) was dried first by keeping over sodium wire for a night and later refluxed on the fractionating column for 24 h and finally, it was distilled off.

**<sup>1</sup>H NMR spectra:** <sup>1</sup>H NMR data were obtained from a BRUKER Advance III NMR spectrometer in DMSO/CDCl<sub>3</sub> solution at 400 MHz frequency using TMS as an internal standard.

**<sup>13</sup>C NMR spectra:** <sup>13</sup>C NMR spectral studies of the new titanium derivatives were performed in DMSO/CDCl<sub>3</sub> solution on a BRUKER Advance III NMR spectrometer at 100 MHz frequency.

**FTIR analysis:** FTIR spectra were taken on a Shimadzu IR affinity 1 spectrometer with anhydrous KBr pellets in the range of 4000-400 cm<sup>-1</sup>.

**Mass analysis:** Mass spectral data of the new titanium(IV) complexes were recorded on HR-Q-ToF mass spectrometer.

**Thermogravimetric analysis:** Thermogravimetric analyses of the new complexes were performed on a TA instrument SDTQ 600, USA at a heating rate of 10 °C/min from 25 °C to 900 °C under flowing nitrogen environment.

**Elemental analysis:** Elemental analyses of the complexes were carried out on an Elementar Vario EL III instrument.

**UV analysis:** The UV-visible spectra were taken over a range of 200-800 cm<sup>-1</sup> using Jasco V-670 UV-Visible spectrophotometer.

**Synthesis of 2-hydroxy-*N*-phenylbenzylamines:** Previously reported method [15] was adopted for the synthesis of various derivatives of 2-hydroxy-*N*-phenylbenzylamines.

**Synthesis of titanium(IV) derivatives:** A previously reported [16] synthetic route was adopted for the synthesis of various new titanium(IV) derivatives.

**Estimation of titanium and isopropanol:** Estimation of titanium was carried out by a known method [17] and chromate oxidimetric method [18] employed for estimating the liberated isopropanol during the reactions.

### Spectral data

**[(*N*-(Phenyl)benzylamine-2-ato)-bis(8-quinolinato)-titanium(IV)] (3a):** Colour: Reddish brown powder; m.p. = 178-180 °C; % Yield: 98.7 %; Alcohol estimation (Pr<sup>i</sup>OH): Calcd. 0.46 g, Found: 0.45 g; UV (DMSO) λ<sub>max</sub> (log ε, nm): 269 (5.45), 304 (5.51); IR (KBr, ν<sub>max</sub>, cm<sup>-1</sup>): 2937, 2912, 2861, 1815, 1749, 1600, 1573, 1494, 1463, 1448, 1373, 1319, 1257, 1105, 1064, 1051, 1010, 898, 821, 786, 740, 711, 628, 422; <sup>1</sup>H NMR (400 MHz, DMSO) δ: 8.47 (2H, dd, *J* = 1.6, 8.0 Hz, H-2, H-2'), 7.83 (2H, dd, *J* = 1.6, 8.0 Hz, H-4, H-4'), 7.45 (2H, dd, *J* = 1.6, 8.0 Hz, H-5, H-5'), 7.10 (2H, dd, *J* = 1.6, 8.0 Hz, H-6, H-6'), 7.06 (1H, t, H-4<sup>#</sup>), 7.02 (1H, t, H-4<sup>\*</sup>), 6.99 (2H, dd, *J* = 1.6, 8.0 Hz, H-3, H-3'), 6.84 (2H, t, H-3<sup>#</sup>, H-5<sup>#</sup>), 6.75 (2H, dd, *J* = 1.6, 8.0 Hz, H-7, H-7'), 6.72 (1H, d, *J* = 6.0 Hz, H-6<sup>\*</sup>), 6.67 (1H, t, H-5<sup>#</sup>), 6.58 (1H, d, *J* = 4.0 Hz, H-3<sup>\*</sup>), 6.54 (1H, d, *J* = 4.8 Hz, H-2<sup>#</sup>), 6.50 (1H, d, *J* = 7.6 Hz, H-6<sup>#</sup>), 4.37 (2H, s, H-1<sup>\*\*</sup>); <sup>13</sup>C NMR (100 MHz, DMSO) δ: 152.5 (C, C-2<sup>\*</sup>), 151.0 (C, C-1<sup>#</sup>), 147.7 (C, C-8, C-8'), 142.0 (CH, C-3<sup>#</sup>), 135.9 (CH, C-2, C-2'), 134.8 (C, C-8a, C-8a'), 133.4 (CH,

C-5<sup>#</sup>), 132.6 (CH, C-4, C-4'), 131.3 (C, C-1<sup>\*</sup>), 130.4 (CH, C-4<sup>#</sup>), 129.6 (C, C-4a, C-4a'), 128.9 (CH, C-6, C-6'), 127.2 (CH, C-5<sup>\*</sup>), 126.1 (CH, C-3<sup>\*</sup>), 125.1 (CH, C-4<sup>\*</sup>, C-5<sup>\*</sup>), 124.9 (CH, C-2<sup>#</sup>, C-6<sup>#</sup>), 123.6 (CH, C-3, C-3'), 120.7 (CH, C-5, C-5'), 118.9 (CH, C-7, C-7'), 53.7 (CH<sub>2</sub>, C-1<sup>\*\*</sup>); HRMS: *m/z* (pos): 533.1222, C<sub>31</sub>H<sub>23</sub>N<sub>3</sub>O<sub>3</sub>Ti (Calcd. 533.1219); Anal. calcd. (%) for C<sub>31</sub>H<sub>23</sub>N<sub>3</sub>O<sub>3</sub>Ti: C, 69.80; H, 4.35; N, 7.88; Ti, 8.97. Found (%) C, 69.92; H, 4.41; N, 7.93; Ti, 8.92.

**[(*N*-(4-Methylphenyl)benzylamine-2-ato)-bis(8-quinolinato)titanium(IV)] (3b):** Colour: Reddish brown powder; m.p. = 181-183 °C; % Yield: 98.1 %; Alcohol estimation (Pr<sup>i</sup>OH): Calcd. 0.44 g, Found: 0.43 g; UV (DMSO) λ<sub>max</sub> (log ε, nm): 267 (5.46), 325 (5.53); IR (KBr, ν<sub>max</sub>, cm<sup>-1</sup>): 2940, 2914, 2860, 1614, 1573, 1494, 1463, 1448, 1373, 1319, 1251, 1236, 1172, 1105, 1029, 1010, 950, 902, 821, 740, 713, 615, 432; <sup>1</sup>H NMR (400 MHz, DMSO) δ: 7.64 (2H, dd, *J* = 1.6, 8.0 Hz, H-2, H-2'), 7.47 (1H, d, *J* = 8.0 Hz, H-6<sup>\*</sup>), 7.36 (1H, d, *J* = 8.0 Hz, H-3<sup>\*</sup>), 7.21 (2H, dd, *J* = 1.6, 8.0 Hz, H-4, H-4'), 7.06 (2H, dd, *J* = 1.6, 8.0 Hz, H-5, H-5'), 6.88 (2H, dd, *J* = 1.6, 8.0 Hz, H-6, H-6'), 6.84 (2H, dd, *J* = 1.6, 8.0 Hz, H-3, H-3'), 6.75 (1H, t, H-4<sup>\*</sup>), 6.60 (2H, dd, *J* = 1.6, 9.6 Hz, H-7, H-7'), 6.52 (1H, d, *J* = 8.4 Hz, H-3<sup>#</sup>), 6.36 (1H, d, *J* = 8.0 Hz, H-5<sup>#</sup>), 6.31 (1H, d, *J* = 8.0 Hz, H-2<sup>#</sup>), 6.22 (1H, d, *J* = 8.0 Hz, H-6<sup>#</sup>), 5.74 (1H, t, H-5<sup>\*</sup>), 4.27 (2H, s, H-1<sup>\*\*</sup>) 2.16 (3H, s, H-4<sup>##</sup>); <sup>13</sup>C NMR (100 MHz, DMSO) δ: 152.5 (C, C-8, C-8'), 151.0 (C, C-2<sup>\*</sup>), 147.7 (CH, C-2, C-2'), 140.0 (C, C-1<sup>#</sup>), 137.2 (C, C-8a, C-8a'), 135.9 (CH, C-4, C-4'), 134.8 (C, C-4a, C-4a'), 133.5 (CH, C-3<sup>#</sup>), 132.2 (CH, C-5<sup>#</sup>), 131.6 (CH, C-6, C-6'), 130.6 (CH, C-3, C-3'), 129.5 (C, C-1<sup>\*</sup>), 127.2 (C, C-4<sup>#</sup>), 125.5 (CH, C-6<sup>\*</sup>), 125.0 (CH, C-5, C-5'), 123.2 (CH, C-4<sup>\*</sup>), 122.6 (CH, C-7, C-7'), 120.7 (CH, C-3<sup>\*</sup>, C-5<sup>\*</sup>), 119.0 (CH, C-2<sup>#</sup>, C-6<sup>#</sup>), 53.8 (CH<sub>2</sub>, C-1<sup>\*\*</sup>), 20.3 (CH<sub>3</sub>, C-4<sup>##</sup>); HRMS: *m/z* (pos): 547.1381, C<sub>32</sub>H<sub>25</sub>N<sub>3</sub>O<sub>3</sub>Ti (Calcd. 547.1375); Anal. calcd. (%) for C<sub>32</sub>H<sub>25</sub>N<sub>3</sub>O<sub>3</sub>Ti: C, 70.36; H, 4.60; N, 7.68; Ti, 8.66. Found (%) C, 70.26; H, 4.61; N, 7.60; Ti, 8.71.

**[(*N*-(4-Methoxyphenyl)benzylamine-2-ato)-bis(8-quinolinato)titanium(IV)] (3c):** Colour: Reddish brown powder; m.p. = 187-189 °C; % Yield: 98.4 %; Alcohol estimation (Pr<sup>i</sup>OH): Calcd. 0.46 g, Found: 0.45 g; UV (DMSO) λ<sub>max</sub> (log ε, nm): 269 (5.48), 320 (5.55); IR (KBr, ν<sub>max</sub>, cm<sup>-1</sup>): 2928, 2905, 2859, 1591, 1573, 1510, 1494, 1463, 1446, 1373, 1319, 1230, 1105, 1004, 898, 821, 740, 711, 615, 430; <sup>1</sup>H NMR (400 MHz, DMSO) δ: 7.77 (2H, dd, *J* = 1.6, 8.0 Hz, H-2, H-2'), 7.43 (2H, dd, *J* = 1.6, 8.0 Hz, H-4, H-4'), 7.39 (2H, dd, *J* = 1.6, 8.0 Hz, H-5, H-5'), 7.16 (2H, dd, *J* = 1.6, 8.0 Hz, H-6, H-6'), 7.08 (1H, d, *J* = 7.6 Hz, H-6<sup>\*</sup>), 7.04 (1H, d, *J* = 8.4 Hz, H-3<sup>\*</sup>), 7.00 (1H, t, H-4<sup>\*</sup>), 6.98 (1H, d, *J* = 7.6 Hz, H-3<sup>#</sup>), 6.80 (2H, dd, *J* = 1.6, 8.0 Hz, H-3, H-3'), 6.63 (1H, d, *J* = 7.6 Hz, H-5<sup>#</sup>), 6.58 (2H, dd, *J* = 1.6, 8.0 Hz, H-7, H-7'), 6.56 (1H, d, *J* = 3.6 Hz, H-2<sup>#</sup>), 6.49 (1H, t, H-5<sup>\*</sup>), 6.42 (1H, d, *J* = 8.8 Hz, H-6<sup>#</sup>), 4.31 (2H, s, H-1<sup>\*\*</sup>), 3.66 (3H, s, H-4<sup>##</sup>); <sup>13</sup>C NMR (100 MHz, DMSO) δ: 155.0 (C, C-2<sup>\*</sup>), 152.5 (C, C-8, C-8'), 151.1 (C, C-4<sup>#</sup>), 147.7 (CH, C-2, C-2'), 136.6 (C, C-1<sup>#</sup>), 134.7 (C, C-8a, C-8a'), 132.6 (CH, C-4, C-4'), 131.7 (C, C-4a, C-4a'), 130.4 (CH, C-6, C-6'), 129.6 (CH, C-4<sup>\*</sup>, C-6<sup>\*</sup>), 128.5 (C, C-1<sup>\*</sup>), 127.1 (CH, C-3<sup>\*</sup>), 125.5 (CH, C-5<sup>\*</sup>), 125.0 (CH, C-3, C-3'), 123.6 (CH, C-5, C-5'), 120.7 (CH, C-7, C-7'), 119.0 (CH, C-3<sup>#</sup>, C-5<sup>#</sup>), 116.9 (CH, C-2<sup>#</sup>, C-6<sup>#</sup>), 55.7 (CH<sub>3</sub>, OCH<sub>3</sub>), 53.9

(CH<sub>2</sub>, C-1<sup>\*\*</sup>); HRMS: *m/z* (pos): 563.1330, C<sub>32</sub>H<sub>25</sub>N<sub>3</sub>O<sub>4</sub>Ti (Calcd. 563.1325); Anal. calcd. (%) for C<sub>32</sub>H<sub>25</sub>N<sub>3</sub>O<sub>4</sub>Ti: C, 68.22; H, 4.47; N, 7.46; Ti, 8.50. Found (%). C, 68.30; H, 4.44; N, 7.53; Ti, 8.54.

**[(N-(2-Chlorophenyl)benzylamine-2-ato)-bis(8-quinolinato)titanium(IV)] (3d):** Colour: Reddish brown powder; m.p. = 182-184 °C; % Yield: 98.2 %; Alcohol estimation (Pr<sup>i</sup>OH): Calcd. 0.48 g, Found: 0.47 g; UV (DMSO) λ<sub>max</sub> (log ε, nm): 262 (5.47), 308 (5.54); IR (KBr, ν<sub>max</sub>, cm<sup>-1</sup>): 2944, 2908, 2847, 1593, 1573, 1494, 1463, 1448, 1373, 1249, 1236, 1126, 1105, 1004, 894, 823, 785, 738, 711, 628, 432; <sup>1</sup>H NMR (400 MHz, DMSO) δ: 8.43 (1H, d, *J* = 7.6 Hz, H-3<sup>#</sup>), 7.86 (2H, dd, *J* = 1.6, 8.0 Hz, H-2, H-2'), 7.79 (1H, t, H-5<sup>#</sup>), 7.71 (1H, d, *J* = 8.0 Hz, H-6<sup>\*</sup>), 7.37 (2H, t, H-4<sup>#</sup>, H-5<sup>\*</sup>), 7.16 (2H, dd, *J* = 1.6, 8.0 Hz, H-4, H-4'), 7.07 (2H, dd, *J* = 1.6, 8.0 Hz, H-5, H-5'), 6.89 (2H, dd, *J* = 1.6, 8.0 Hz, H-6, H-6'), 6.84 (1H, d, *J* = 8.0 Hz, H-3<sup>\*</sup>), 6.62 (1H, d, *J* = 8.0 Hz, H-6<sup>#</sup>), 6.46 (2H, dd, *J* = 1.6, 8.0 Hz, H-3, H-3'), 6.43 (1H, t, H-4<sup>\*</sup>), 6.32 (2H, dd, *J* = 1.6, 8.0 Hz, H-7, H-7'), 4.21 (2H, s, H-1<sup>\*\*</sup>); <sup>13</sup>C NMR (100 MHz, DMSO) δ: 152.7 (C, C-8, C-8'), 151.1 (C, C-2<sup>\*</sup>), 147.7 (CH, C-2, C-2'), 142.2 (C, C-8a, C-8a'), 137.9 (C, C-1<sup>#</sup>), 136.7 (CH, C-3<sup>#</sup>), 135.2 (C, C-1<sup>\*</sup>), 134.2 (CH, C-4, C-4'), 133.6 (C, C-4a, C-4a'), 132.2 (CH, C-6<sup>\*</sup>), 131.3 (CH, C-4<sup>\*</sup>), 130.3 (CH, C-5<sup>#</sup>), 129.6 (CH, C-6, C-6'), 127.3 (CH, C-4<sup>#</sup>), 126.3 (C, C-2<sup>#</sup>), 125.4 (CH, C-5<sup>\*</sup>), 124.9 (CH, C-3, C-3'), 123.5 (CH, C-5, C-5'), 120.7 (CH, C-7, C-7'), 119.0 (CH, C-3<sup>\*</sup>, C-6<sup>#</sup>), 53.6 (CH<sub>2</sub>, C-1<sup>\*\*</sup>); HRMS: *m/z* (pos): 567.0834, C<sub>31</sub>H<sub>22</sub>ClN<sub>3</sub>O<sub>3</sub>Ti (Calcd. 567.0829); Anal. calcd. (%) for C<sub>31</sub>H<sub>22</sub>ClN<sub>3</sub>O<sub>3</sub>Ti: C, 65.57; H, 3.91; N, 7.40; Ti, 8.43. Found (%). C, 65.60; H, 3.92; N, 7.43; Ti, 8.41.

**[(N-(4-Chlorophenyl)benzylamine-2-ato)-bis(8-quinolinato)titanium(IV)] (3e):** Colour: Reddish brown powder; m.p. = 197-199 °C; % Yield: 98.6 %; Alcohol estimation (Pr<sup>i</sup>OH): Calcd. 0.50 g, Found: 0.49 g; UV (DMSO) λ<sub>max</sub> (log ε, nm): 268 (5.48), 314 (5.55); IR (KBr, ν<sub>max</sub>, cm<sup>-1</sup>): 2956, 2912, 2862, 1597, 1573, 1494, 1463, 1448, 1373, 1319, 1251, 1236, 1174, 1126, 1105, 1002, 896, 823, 785, 742, 709, 628, 438; <sup>1</sup>H NMR (400 MHz, DMSO) δ: 8.51 (2H, dd, *J* = 1.6, 8.0 Hz, H-2, H-2'), 7.98 (2H, dd, *J* = 1.6, 8.0 Hz, H-4, H-4'), 7.86 (2H, dd, *J* = 1.6, 8.0 Hz, H-5, H-5'), 7.74 (1H, t, H-4<sup>\*</sup>), 7.42 (2H, dd, *J* = 1.6, 8.0 Hz, H-6, H-6'), 7.36 (2H, dd, *J* = 1.6, 8.0 Hz, H-3, H-3'), 7.23 (1H, t, H-5<sup>\*</sup>), 7.15 (1H, d, *J* = 8.0 Hz, H-6<sup>\*</sup>), 6.98 (2H, d, *J* = 8.0 Hz, H-3<sup>#</sup>, H-5<sup>#</sup>), 6.92 (1H, d, *J* = 8.0 Hz, H-3<sup>\*</sup>), 6.86 (2H, dd, *J* = 1.6, 8.0 Hz, H-7, H-7'), 6.29 (2H, d, *J* = 8.4 Hz, H-2<sup>#</sup>, H-6<sup>#</sup>), 4.33 (2H, s, H-1<sup>\*\*</sup>); <sup>13</sup>C NMR (100 MHz, DMSO) δ: 152.5 (C, C-8, C-8'), 151.1 (C, C-2<sup>\*</sup>), 147.7 (CH, C-2, C-2'), 140.7 (C, C-1<sup>#</sup>), 135.7 (C, C-8a, C-8a'), 134.9 (CH, C-4, C-4'), 133.7 (C, C-4a, C-4a'), 132.7 (C, C-1<sup>\*</sup>), 131.9 (CH, C-6, C-6'), 130.6 (CH, C-3<sup>#</sup>, C-5<sup>#</sup>), 129.5 (C, C-4<sup>#</sup>), 127.1 (CH, C-5<sup>\*</sup>), 125.9 (CH, C-3<sup>\*</sup>), 124.9 (CH, C-4<sup>\*</sup>, C-6<sup>\*</sup>), 123.6 (CH, C-3, C-3'), 122.6 (CH, C-5, C-5'), 120.7 (CH, C-7, C-7'), 119.0 (CH, C-2<sup>#</sup>, C-6<sup>#</sup>), 53.9 (CH<sub>2</sub>, C-1<sup>\*\*</sup>); HRMS: *m/z* (pos): 567.0832, C<sub>31</sub>H<sub>22</sub>ClN<sub>3</sub>O<sub>3</sub>Ti (Calcd. 567.0829); Anal. calcd. (%) for C<sub>31</sub>H<sub>22</sub>ClN<sub>3</sub>O<sub>3</sub>Ti: C, 65.57; H, 3.91; N, 7.40; Ti, 8.43. Found (%). C, 65.78; H, 3.86; N, 7.54; Ti, 8.33.

**[(N-(Phenyl)-5-bromobenzylamine-2-ato)-bis(8-quinolinato)titanium(IV)] (3f):** Colour: Reddish brown powder;

m.p. = 189-190 °C; % Yield: 98.1 %; Alcohol estimation (Pr<sup>i</sup>OH): Calcd. 0.49 g, Found: 0.48 g; UV (DMSO) λ<sub>max</sub> (log ε, nm): 263 (5.50), 322 (5.55); IR (KBr, ν<sub>max</sub>, cm<sup>-1</sup>): 2952, 2911, 2867, 1732, 1600, 1573, 1494, 1463, 1373, 1319, 1259, 1170, 1122, 1105, 1004, 902, 821, 785, 742, 717, 628, 465; <sup>1</sup>H NMR (400 MHz, DMSO) δ: 8.50 (2H, dd, *J* = 1.6, 8.0 Hz, H-2, H-2'), 8.40 (2H, dd, *J* = 1.6, 8.0 Hz, H-4, H-4'), 8.35 (2H, dd, *J* = 1.6, 8.0 Hz, H-5, H-5'), 7.98 (1H, d, *J* = 8.0 Hz, H-4<sup>\*</sup>), 7.92 (1H, d, *J* = 8.0 Hz, H-3<sup>\*</sup>), 7.84 (2H, dd, *J* = 1.6, 8.0 Hz, H-6, H-6'), 7.75 (1H, d, *J* = 8.0 Hz, H-2<sup>#</sup>), 7.43 (1H, t, H-3<sup>#</sup>), 7.38 (2H, dd, *J* = 1.6, 8.0 Hz, H-3, H-3'), 7.13 (1H, t, H-5<sup>#</sup>), 7.09 (1H, s, H-6<sup>\*</sup>), 6.89 (1H, dt, H-4<sup>#</sup>), 6.56 (2H, dd, *J* = 1.6, 8.0 Hz, H-7, H-7'), 6.38 (1H, d, *J* = 7.6 Hz, H-6<sup>#</sup>), 4.2 (2H, s, H-1<sup>\*\*</sup>); <sup>13</sup>C NMR (100 MHz, DMSO) δ: 152.5 (C, C-8, C-8'), 150.1 (C, C-2<sup>\*</sup>), 147.7 (CH, C-2, C-2'), 142.1 (C, C-1<sup>#</sup>), 136.8 (C, C-1<sup>\*</sup>), 135.3 (C, C-8a, C-8a'), 134.3 (CH, C-4<sup>\*</sup>), 133.8 (CH, C-4, C-4'), 132.2 (CH, C-6<sup>\*</sup>), 131.4 (C, C-4a, C-4a'), 129.6 (CH, C-3<sup>#</sup>, C-5<sup>#</sup>), 128.9 (CH, C-6, C-6'), 127.2 (CH, C-4<sup>#</sup>), 126.3 (CH, C-5<sup>\*</sup>), 124.9 (CH, C-3, C-3'), 123.3 (CH, C-5, C-5'), 120.7 (CH, C-7, C-7'), 118.9 (CH, C-2<sup>#</sup>, C-6<sup>#</sup>), 112.4 (CH, C-3<sup>\*</sup>), 55.2 (CH<sub>2</sub>, C-1<sup>\*\*</sup>); HRMS: *m/z* (pos): 611.0330, C<sub>31</sub>H<sub>22</sub>BrN<sub>3</sub>O<sub>3</sub>Ti (Calcd. 611.0324); Anal. calcd. (%) for C<sub>31</sub>H<sub>22</sub>BrN<sub>3</sub>O<sub>3</sub>Ti: C, 60.81; H, 3.62; N, 6.86; Ti, 7.82. Found (%). C, 60.94; H, 3.51; N, 6.94; Ti, 7.93.

**[(N-(4-Methylphenyl)-5-bromobenzylamine-2-ato)-bis(8-quinolinato)titanium(IV)] (3g):** Colour: Reddish brown powder; m.p. = 192-194 °C; % Yield: 98.6 %; Alcohol estimation (Pr<sup>i</sup>OH): Calcd. 0.50 g, Found: 0.49 g; UV (DMSO) λ<sub>max</sub> (log ε, nm): 264 (5.51), 315 (5.59); IR (KBr, ν<sub>max</sub>, cm<sup>-1</sup>): 2944, 2900, 2845, 1815, 1724, 1614, 1573, 1519, 1494, 1462, 1373, 1319, 1257, 1236, 1122, 1105, 1082, 1002, 902, 823, 806, 785, 742, 715, 665, 430; <sup>1</sup>H NMR (400 MHz, DMSO) δ: 8.51 (2H, dd, *J* = 1.6, 8.0 Hz, H-2, H-2'), 8.41 (2H, dd, *J* = 1.6, 8.0 Hz, H-4, H-4'), 8.36 (1H, d, *J* = 8.0 Hz, H-3<sup>#</sup>), 7.99 (2H, dd, *J* = 1.6, 8.0 Hz, H-5, H-5'), 7.94 (2H, dd, *J* = 1.6, 8.0 Hz, H-6, H-6'), 7.86 (2H, dd, *J* = 1.6, 8.0 Hz, H-3, H-3'), 7.45 (2H, dd, *J* = 1.6, 8.0 Hz, H-7, H-7'), 7.41 (1H, d, *J* = 8.0 Hz, H-4<sup>\*</sup>), 7.07 (1H, s, H-6<sup>\*</sup>), 7.04 (1H, d, *J* = 8.8 Hz, H-5<sup>#</sup>), 6.77 (1H, d, *J* = 6.0 Hz, H-3<sup>\*</sup>), 6.57 (1H, d, *J* = 8.0 Hz, H-2<sup>#</sup>), 6.31 (1H, d, *J* = 8.0 Hz, H-6<sup>#</sup>), 4.22 (2H, s, H-1<sup>\*\*</sup>), 2.12 (3H, CH<sub>3</sub>, H-4<sup>##</sup>); <sup>13</sup>C NMR (100 MHz, DMSO) δ: 152.5 (C, C-8, C-8'), 150.1 (C, C-2<sup>\*</sup>), 147.7 (CH, C-2, C-2'), 140.0 (C, C-1<sup>#</sup>), 137.8 (C, C-1<sup>\*</sup>), 136.3 (CH, C-4<sup>\*</sup>), 135.7 (C, C-8a, C-8a'), 134.5 (CH, C-4, C-4'), 132.9 (C, C-4a, C-4a'), 131.5 (CH, C-6<sup>\*</sup>), 130.6 (CH, C-6, C-6'), 129.6 (CH, C-3<sup>#</sup>, C-5<sup>#</sup>), 128.9 (C, C-4<sup>#</sup>), 126.3 (C, C-5<sup>\*</sup>), 124.9 (CH, C-3, C-3'), 123.6 (CH, C-5, C-5'), 120.7 (CH, C-7, C-7'), 118.9 (CH, C-2<sup>#</sup>, C-6<sup>#</sup>), 112.4 (CH, C-3<sup>\*</sup>), 55.4 (CH<sub>2</sub>, C-1<sup>\*\*</sup>), 20.3 (CH<sub>3</sub>, C-4<sup>##</sup>); HRMS: *m/z* (pos): 625.0489, C<sub>32</sub>H<sub>24</sub>BrN<sub>3</sub>O<sub>3</sub>Ti (Calcd. 625.0481); Anal. calcd. (%) for C<sub>32</sub>H<sub>24</sub>BrN<sub>3</sub>O<sub>3</sub>Ti: C, 61.36; H, 3.86; N, 6.71; Ti, 7.64. Found (%). C, 61.42; H, 3.90; N, 6.75; Ti, 7.67.

**[(N-(4-Methoxyphenyl)-5-bromobenzylamine-2-ato)-bis(8-quinolinato)titanium(IV)] (3h):** Colour: Reddish brown powder; m.p. = 195-197 °C; % Yield: 98.2 %; Alcohol estimation (Pr<sup>i</sup>OH): Calcd. 0.44 g, Found: 0.43 g; UV (DMSO) λ<sub>max</sub> (log ε, nm): 263 (5.52), 330 (5.61); IR (KBr, ν<sub>max</sub>, cm<sup>-1</sup>): 2932, 2904, 2856, 1573, 1462, 1373, 1319, 1259, 1230, 1172, 1105, 1002, 900, 819, 785, 742, 715, 628, 613, 484; <sup>1</sup>H NMR (400



MHz, DMSO)  $\delta$ : 8.51 (2H, dd,  $J = 1.6, 8.0$  Hz, H-2, H-2'), 8.42 (2H, dd,  $J = 1.6, 8.0$  Hz, H-4, H-4'), 8.02 (2H, dd,  $J = 1.6, 8.0$  Hz, H-5, H-5'), 7.97 (2H, dd,  $J = 1.6, 8.0$  Hz, H-6, H-6'), 7.89 (2H, dd,  $J = 1.6, 8.0$  Hz, H-3, H-3'), 7.79 (1H, d,  $J = 8.0$  Hz, H-4\*), 7.50 (2H, dd,  $J = 1.6, 8.0$  Hz, H-7, H-7'), 7.46 (1H, d,  $J = 8.0$  Hz, H-3\*), 7.37 (1H, d,  $J = 8.0$  Hz, H-3\*), 7.17 (1H, s, H-6\*), 7.03 (1H, d,  $J = 8.0$  Hz, H-5\*), 6.57 (1H, d,  $J = 8.0$  Hz, H-2\*), 6.35 (1H, d,  $J = 8.0$  Hz, H-6\*), 4.09 (2H, s, H-1\*\*), 3.63 (3H, OCH<sub>3</sub>, H-4\*\*); <sup>13</sup>C NMR (100 MHz, DMSO)  $\delta$ : 153.7 (C, C-8, C-8'), 151.1 (C, C-2\*), 148.7 (CH, C-2, C-2'), 140.2 (C, C-1\*), 137.6 (C, C-1\*), 136.5 (CH, C-4\*), 135.6 (C, C-8a, C-8a'), 133.9 (CH, C-4, C-4'), 132.9 (C, C-4a, C-4a'), 131.5 (CH, C-6\*), 130.9 (CH, C-6, C-6'), 129.6 (CH, C-3#, C-5#), 128.3 (C, C-4\*), 125.9 (C, C-5\*), 124.4 (CH, C-3, C-3'), 122.9 (CH, C-5, C-5'), 120.4 (CH, C-7, C-7'), 117.3 (CH, C-2#, C-6#), 111.8 (CH, C-3\*), 55.7 (CH<sub>2</sub>, C-1\*\*), 21.9 (CH<sub>3</sub>, C-4\*\*); HRMS:  $m/z$  (pos): 641.0434, C<sub>32</sub>H<sub>24</sub>BrN<sub>3</sub>O<sub>4</sub>Ti (Calcd. 641.0430); Anal. calcd. (%) for C<sub>32</sub>H<sub>24</sub>BrN<sub>3</sub>O<sub>4</sub>Ti: C, 59.84; H, 3.77; N, 6.54; Ti, 7.45. Found (%). C, 59.92; H, 3.81; N, 6.53; Ti, 7.57.

**[(N-(2-Bromophenyl)-5-bromobenzylamine-2-ato)-bis(8-quinolinato)titanium(IV)] (3i)**: Colour: Reddish brown powder; m.p. = 189-191 °C; % Yield: 97.8 %; Alcohol estimation (Pr<sup>i</sup>OH): Calcd. 0.47 g, Found: 0.46 g; UV (DMSO)  $\lambda_{\max}$  (log  $\epsilon$ , nm): 264 (5.53), 320 (5.58); IR (KBr,  $\nu_{\max}$ , cm<sup>-1</sup>): 2946, 2911, 2842, 1726, 1597, 1573, 1494, 1462, 1456, 1373, 1361, 1319, 1282, 1236, 1124, 1105, 1082, 1004, 898, 821, 785, 740, 717, 628, 461; <sup>1</sup>H NMR (400 MHz, DMSO)  $\delta$ : 8.50 (2H, dd,  $J = 1.6, 8.0$  Hz, H-2, H-2'), 8.41 (1H, d,  $J = 8.0$  Hz, H-3\*), 8.35 (2H, dd,  $J = 1.6, 8.0$  Hz, H-4, H-4'), 7.98 (1H, d,  $J = 8.0$  Hz, H-4\*), 7.92 (1H, d,  $J = 8.0$  Hz, H-3\*), 7.42 (2H, dd,  $J = 1.6, 8.0$  Hz, H-5, H-5'), 7.37 (2H, dd,  $J = 1.6, 8.0$  Hz, H-6, H-6'), 7.17 (1H, s, H-6\*), 7.09 (2H, dd,  $J = 1.6, 8.0$  Hz, H-3, H-3'), 6.91 (2H, dd,  $J = 1.6, 8.0$  Hz, H-7, H-7'), 6.72 (1H, t, H-5#), 6.60 (1H, dt, H-4#), 6.34 (1H, d,  $J = 8.0$  Hz, H-6\*), 4.12 (2H, s, CH<sub>2</sub>, H-1\*\*); <sup>13</sup>C NMR (100 MHz, DMSO)  $\delta$ : 153.4 (C, C-8, C-8'), 151.1 (C, C-2\*), 146.9 (CH, C-2, C-2'), 141.4 (C, C-1\*), 136.1 (C, C-1\*), 134.6 (CH, C-4\*), 134.0 (C, C-8a, C-8a'), 132.9 (CH, C-6\*), 132.5 (CH, C-4, C-4'), 131.2 (C, C-4a, C-4a'), 130.5 (CH, C-6, C-6'), 129.8 (CH, C-3#, C-5#), 128.5 (CH, C-4\*), 126.6 (C, C-2#), 124.4 (CH, C-3, C-3'), 122.7 (CH, C-5, C-5'), 120.5 (CH, C-7, C-7'), 117.4 (CH, C-6#; C, C-5\*), 112.9 (CH, C-3\*), 53.2 (CH<sub>2</sub>, C-1\*\*); HRMS:  $m/z$  (pos): 688.9438, C<sub>31</sub>H<sub>21</sub>Br<sub>2</sub>N<sub>3</sub>O<sub>3</sub>Ti (Calcd. 688.9429); Anal. calcd. (%) for C<sub>31</sub>H<sub>21</sub>Br<sub>2</sub>N<sub>3</sub>O<sub>3</sub>Ti: C, 53.87; H, 3.06; N, 6.08; Ti, 6.93. Found (%). C, 53.93; H, 3.15; N, 6.14; Ti, 7.02.

**[(N-(4-Bromophenyl)-5-bromobenzylamine-2-ato)-bis(8-quinolinato)titanium(IV)] (3j)**: Colour: Reddish brown powder; m.p. = 185-187 °C; % Yield: 98.3 %; Alcohol estimation (Pr<sup>i</sup>OH): Calcd. 0.49 g, Found: 0.48 g; UV (DMSO)  $\lambda_{\max}$  (log  $\epsilon$ , nm): 265 (5.53), 324 (5.60); IR (KBr,  $\nu_{\max}$ , cm<sup>-1</sup>): 2967, 2919, 2859, 1726, 1598, 1573, 1494, 1462, 1456, 1373, 1361, 1319, 1259, 1236, 1172, 1122, 1105, 1078, 1002, 902, 806, 785, 742, 713, 628, 439; <sup>1</sup>H NMR (400 MHz, DMSO)  $\delta$ : 8.51 (2H, dd,  $J = 1.6, 8.0$  Hz, H-2, H-2'), 8.35 (2H, dd,  $J = 1.6, 8.0$  Hz, H-4, H-4'), 8.02 (2H, dd,  $J = 1.6, 8.0$  Hz, H-5, H-5'), 7.89 (2H, dd,  $J = 1.6, 8.0$  Hz, H-6, H-6'), 7.80 (1H, d,  $J = 8.0$  Hz, H-3\*), 7.48 (2H, dd,  $J = 1.6, 8.0$  Hz, H-3, H-3'), 7.44 (2H, dd,

$J = 1.6, 8.0$  Hz, H-7, H-7'), 7.15 (1H, d,  $J = 8.0$  Hz, H-5\*), 7.13 (1H, s, H-6\*), 6.88 (1H, d,  $J = 8.0$  Hz, H-4\*), 6.56 (1H, d,  $J = 8.0$  Hz, H-3\*), 6.43 (1H, d,  $J = 8.0$  Hz, H-2\*), 6.25 (1H, d,  $J = 8.0$  Hz, H-6\*), 4.28 (2H, s, CH<sub>2</sub>, H-1\*\*); <sup>13</sup>C NMR (100 MHz, DMSO)  $\delta$ : 152.5 (C, C-8, C-8'), 150.2 (C, C-2\*), 147.7 (CH, C-2, C-2'), 140.8 (C, C-1\*), 137.3 (C, C-1\*), 136.8 (CH, C-4\*), 134.7 (C, C-8a, C-8a'), 133.3 (CH, C-6\*), 132.2 (CH, C-4, C-4'), 131.7 (C, C-4a, C-4a'), 130.9 (CH, C-6, C-6'), 129.6 (CH, C-3#, C-5#), 128.9 (CH, C-4\*), 126.3 (C, C-5\*), 125.0 (CH, C-3, C-3'), 123.6 (CH, C-5, C-5'), 120.7 (CH, C-7, C-7'), 118.9 (CH, C-2#, C-6#), 112.4 (CH, C-3\*), 55.4 (CH<sub>2</sub>, C-1\*\*); HRMS:  $m/z$  (pos): 688.9436, C<sub>31</sub>H<sub>21</sub>Br<sub>2</sub>N<sub>3</sub>O<sub>3</sub>Ti (Calcd. 688.9429); Anal. calcd. (%) for C<sub>31</sub>H<sub>21</sub>Br<sub>2</sub>N<sub>3</sub>O<sub>3</sub>Ti: C, 53.87; H, 3.06; N, 6.08; Ti, 6.93. Found (%). C, 53.91; H, 3.11; N, 6.13; Ti, 7.01 (The numbering followed for the NMR interpretation is indicated in Fig. 1).




Fig. 1. Numbering followed for the NMR interpretation of the complexes

**Cytotoxicity evaluation:** The cytotoxicity ability of the newly synthesized derivatives was carried out on MDA-MB-231 human breast carcinoma cell line. The cell line was obtained from National Centre for Cell Science (Pune, India). Already existing procedures [19,20] were adopted for the evaluating cytotoxicity.

## RESULTS AND DISCUSSION

The precursor titanium tetraisopropoxide [Ti(OPri)<sub>4</sub>] (**1**) reacts with the bidentate ligand 8-hydroxyquinoline in 1:2 molar ratio in anhydrous toluene and produces the complex [(Q)<sub>2</sub>Ti(OPri)<sub>2</sub>] (**2**). Complex **2**, on treating further with 2-hydroxy-N-phenylbenzylamine in equimolar ratio produces titanium complexes of general formula [(Q)<sub>2</sub>Ti(2-O-5-X-C<sub>6</sub>H<sub>3</sub>CH<sub>2</sub>NC<sub>6</sub>H<sub>4</sub>R)] (**3a-j**) as given in **Scheme-1**.

With the progress of the reaction, free isopropanol gets released in the reaction mixture. The reaction mixture containing toluene-isopropanol azeotrope was then subjected to iodometric titration for the evaluation of reaction advancement. All the reactions were very rapid and completed in 4-5 h. The newly synthesized derivatives were pale yellow in appearance with quantitative yields. These complexes are insoluble in most of the organic solvents except in DMSO and purified with anhydrous acetonitrile and toluene. Mono-nuclearity of all these complexes has been proved through mass spectra. Various substituents used for the synthesis of complexes are shown depicted in Table-1.

**Elemental analysis:** Elemental analyses have been carried out in order to identify the percentage of various elements present in the newly synthesized titanium complexes. The results were very close to their theoretical values. The analysis results reaffirmed the mono-nuclearity of these complexes.






Fig. 2. UV-visible absorption overtime for [(*N*-(4-methoxyphenyl)-5-bromobenzylamine-2-ato)-bis(8-quinolinato)titanium(IV)] (**3h**) upon addition of water

It has been found from the *in-vitro* study that all these new derivatives (**3a-j**) have substantial antitumor activity against the cell line tested. Complex **3a** showed the highest potential of 0.039  $\mu\text{M}$  against 0.017  $\mu\text{M}$  of cisplatin [25]. The higher activity of this complex compared to all its analogues is due to the presence of smaller and potent Schiff's base ligands. Additionally, complex **3e** was found as the least active molecule in this series and its low antiproliferative activity presumably due to the presence of bulky electron-withdrawing group in the complex. Antitumor efficiency of 4-methyl substituted titanium(IV) derivative has been found as moderate. However, a decrease in activity was observed while replacing the methyl group with a methoxy moiety. This difference in activity is because of the larger methoxy group. Complex without any substitution on the aniline moiety exhibited more cytotoxic potential than complexes with various substitutions. The cytotoxicity potential of complexes (**3a-j**) is depicted in Table-2.

Compd.	IC <sub>50</sub> ( $\mu\text{M}$ )	Compd.	IC <sub>50</sub> ( $\mu\text{M}$ )
<b>3a</b>	0.0394 $\pm$ 0.0039	<b>3g</b>	0.1366 $\pm$ 0.0052
<b>3b</b>	0.0877 $\pm$ 0.0057	<b>3h</b>	0.1346 $\pm$ 0.0019
<b>3c</b>	0.1279 $\pm$ 0.0033	<b>3i</b>	0.1142 $\pm$ 0.0027
<b>3d</b>	0.0748 $\pm$ 0.0084	<b>3j</b>	0.1316 $\pm$ 0.0048
<b>3e</b>	0.1674 $\pm$ 0.0091	Cisplatin	0.0166 $\pm$ 0.0047
<b>3f</b>	0.0474 $\pm$ 0.0049	–	–

( $\pm$  = Standard error)

## Conclusion

The stability study confirms that all the newly synthesized titanium(IV) derivatives have an ability to withstand in a moist environment for a period of 96 h. The NMR and UV-visible spectra are the direct proof of their stability. The binding of titanium(IV) through nitrogen and oxygen atoms have been confirmed by IR and NMR spectroscopy. Elemental analyses and TGA results were in accordance with the theoretical values. Monomeric nature of all these derivatives had been confirmed through mass spectra. Therefore, based on the available literature and the characterization data, *cis*-octahedral geometry had been proposed around titanium(IV) with hexa-coordi-

nation for these newly synthesized titanium(IV) complexes, which were derived from various derivatives of 2-hydroxy-*N*-phenylbenzylamines. Fig. 3 represents the proposed tentative structure of the newly synthesized Ti(IV) derivatives.




Fig. 3. Proposed structure of the titanium(IV) derivatives

## ACKNOWLEDGEMENTS

The authors thank St. Theresa International College, Bangkok, Thailand and Vellore Institute of Technology, Vellore, India for providing necessary facilities to carry out this project work.

## CONFLICT OF INTEREST

The authors declare that there is no conflict of interests regarding the publication of this article.

## REFERENCES

- F. Bray, J. Ferlay, I. Soerjomataram, R.L. Siegel, L.A. Torre and A. Jemal, *CA Cancer J. Clin.*, **68**, 394 (2018); <https://doi.org/10.3322/caac.21492>
- J. Ferlay, M. Colombet, I. Soerjomataram, T. Dyba, G. Randi, M. Bettio, A. Gavin, O. Visser and F. Bray, *Eur. J. Cancer*, **103**, 356 (2018); <https://doi.org/10.1016/j.ejca.2018.07.005>
- U. Ndagi, N. Mhlongo and M.E. Soliman, *Drug Des. Devel. Ther.*, **11**, 599 (2017); <https://doi.org/10.2147/DDDT.S119488>
- Y. Ellahioui, S. Prashar and S. Gómez-Ruiz, *Inorganics*, **5**, 4 (2017); <https://doi.org/10.3390/inorganics5010004>
- P. Koepf-Maier and H. Koepf, *Chem. Rev.*, **87**, 1137 (1987); <https://doi.org/10.1021/cr00081a012>
- H. Glasner and E.Y. Tshuva, *Inorg. Chem. Commun.*, **53**, 31 (2015); <https://doi.org/10.1016/j.inoche.2015.01.019>
- B.K. Keppler, C. Friesen, H.G. Moritz, H. Vongerichten and E. Vogel, *Struct. Bonding*, **78**, 97 (1991); [https://doi.org/10.1007/3-540-54261-2\\_2](https://doi.org/10.1007/3-540-54261-2_2)
- A. Tzuberly, N. Melamed-Book and E.Y. Tshuva, *Dalton Trans.*, **47**, 3669 (2018); <https://doi.org/10.1039/C7DT04828A>
- S. Meeker, O. Braitbard, M.D. Hall, J. Hochman and E.Y. Tshuva, *Chemistry*, **22**, 9849 (2016); <https://doi.org/10.1002/chem.201602626>
- M. Miller and E.Y. Tshuva, *Sci. Rep.*, **8**, 9705 (2018); <https://doi.org/10.1038/s41598-018-27735-0>
- E.Y. Tshuva and D. Peri, *Coord. Chem. Rev.*, **253**, 2098 (2009); <https://doi.org/10.1016/j.ccr.2008.11.015>
- J. Schur, C.M. Manna, A. Deally, R.W. Köster, M. Tacke, E.Y. Tshuva and I. Ott, *Chem. Commun.*, **49**, 4785 (2013); <https://doi.org/10.1039/c3cc38604j>
- W.F. Zeng, Y.S. Chen, M.Y. Chiang, S.S. Chern and C.P. Cheng, *Polyhedron*, **21**, 1081 (2002); [https://doi.org/10.1016/S0277-5387\(02\)00873-2](https://doi.org/10.1016/S0277-5387(02)00873-2)

14. W.F. Zeng, Y.H. Chen, M.Y. Chiang and C.P. Cheng, *Polyhedron*, **26**, 1303 (2007);  
<https://doi.org/10.1016/j.poly.2006.10.048>
15. R. Andreu and J.C. Ronda, *Synth. Commun.*, **38**, 2316 (2008);  
<https://doi.org/10.1080/00397910802138629>
16. B. Samuel and M. Pathak, *Asian J. Chem.*, **31**, 1629 (2019);  
<https://doi.org/10.14233/ajchem.2019.22120>
17. A.I. Vogel, *A Textbook of Quantitative Inorganic Analysis*, Longman: London, edn. 5, pp. 228-229 (1989).
18. D.C. Bradley, F.M.A. Halim, R.C. Mehrotra and W. Wardlaw, *J. Chem. Soc.*, 4609 (1952);  
<https://doi.org/10.1039/JR9520004609>
19. N.D.R. Kumar, V.C. George, P.K. Suresh and R.A. Kumar, *Asian J. Pharm. Clin. Res.*, **5**, 189 (2012).
20. O.S. Weislow, R. Kiser, D.L. Fine, J. Bader, R.H. Shoemaker and M.R. Boyd, *J. Natl. Cancer Inst.*, **81**, 577 (1989);  
<https://doi.org/10.1093/jnci/81.8.577>
21. A. Obeid, A. El-Shekeil, S. Al-Aghbari and J. Al-Shabi, *J. Coord. Chem.*, **65**, 2762 (2012);  
<https://doi.org/10.1080/00958972.2012.703780>
22. M.N. Uddin, D.A. Chowdhury and K. Hossain, *J. Chin. Chem. Soc.*, **59**, 1520 (2012);  
<https://doi.org/10.1002/jccs.201200169>
23. H.A.R. Pramanik, D. Das, P.C. Paul, P. Mondal and C.R. Bhattacharjee, *J. Mol. Struct.*, **1059**, 309 (2014);  
<https://doi.org/10.1016/j.molstruc.2013.12.009>
24. S.A. Sadeek, W.H. Elshwiniy and M.S. Elattar, *Spectrochim. Acta A Mol. Biomol. Spectrosc.*, **84**, 99 (2011);  
<https://doi.org/10.1016/j.saa.2011.09.010>
25. N.C. Campanella, M.S. Demartini, C. Torres, E.T. Almeida and C.M.C.P. Gouvea, *Genet. Mol. Biol.*, **35**, 159 (2012);  
<https://doi.org/10.1590/S1415-47572012005000016>